-
公开(公告)号:US20140228285A1
公开(公告)日:2014-08-14
申请号:US14126215
申请日:2012-06-14
IPC分类号: C07K14/62
CPC分类号: C07K14/622 , C07K1/1077 , C07K14/62
摘要: The present invention regards an insulin derivative comprising at least 2 albumin binding moieties, wherein said albumin binding moieties comprise fatty diacid substitutions and a method for preparing such an insulin derivative by acylation and/or reductive alkylation. The present invention also concern a pharmaceutical comprising such an insulin derivative.
摘要翻译: 本发明涉及包含至少2个白蛋白结合部分的胰岛素衍生物,其中所述白蛋白结合部分包含脂肪二酸取代和通过酰化和/或还原烷基化制备这种胰岛素衍生物的方法。 本发明还涉及包含这种胰岛素衍生物的药物。
-
公开(公告)号:US20110105720A1
公开(公告)日:2011-05-05
申请号:US12922117
申请日:2009-03-13
申请人: Peter Madsen , Thomas Børglum Kjeldsen , Thomas Hoeg-Jensen , Palle Jakobsen , Tina Møller Tagmose , Tine Glendorf , Jånos Tibor Kodra , Patrick William Garibay , Jacob Sten Petersen
发明人: Peter Madsen , Thomas Børglum Kjeldsen , Thomas Hoeg-Jensen , Palle Jakobsen , Tina Møller Tagmose , Tine Glendorf , Jånos Tibor Kodra , Patrick William Garibay , Jacob Sten Petersen
IPC分类号: C07K14/62
摘要: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
摘要翻译: 对蛋白酶具有抗性的新型酰化胰岛素类似物可以有效地被肺或口服给药。 胰岛素类似物含有B25H和A14E或A14H。
-
公开(公告)号:US20050203108A1
公开(公告)日:2005-09-15
申请号:US10980199
申请日:2004-11-03
申请人: Jesper Lau , Peter Madsen , Christian Sams , Carsten Behrens , Josef Vagner , Inge Christensen , Behrend Lundt , Ulla Sidelmann , Henning Thogersen , Anthony Ling , Michael Plewe , Larry Truesdale , Anker Jogensen , Janos Kodra , Shenghua Shi
发明人: Jesper Lau , Peter Madsen , Christian Sams , Carsten Behrens , Josef Vagner , Inge Christensen , Behrend Lundt , Ulla Sidelmann , Henning Thogersen , Anthony Ling , Michael Plewe , Larry Truesdale , Anker Jogensen , Janos Kodra , Shenghua Shi
IPC分类号: C07C237/36 , C07C237/42 , C07C243/38 , C07C271/56 , C07C271/58 , C07C275/24 , C07C275/26 , C07C275/28 , C07C275/30 , C07C275/34 , C07C275/36 , C07C275/38 , C07C275/42 , C07C275/60 , C07C275/62 , C07C311/47 , C07C317/22 , C07C317/32 , C07C317/42 , C07C323/21 , C07C323/44 , C07D209/08 , C07D209/48 , C07D211/58 , C07D213/75 , C07D215/38 , C07D231/40 , C07D235/30 , C07D257/06 , C07D277/72 , C07D295/13 , C07D295/135 , C07D307/68 , C07D317/66 , C07D319/18 , C07D319/20 , C07D333/20 , C07D333/38 , C07D333/60 , C07D333/68 , C07D333/70 , C07D409/12 , C07D417/12 , C07D487/04 , A61K31/519 , A61K31/415 , A61K31/445
CPC分类号: C07D209/48 , C07B2200/07 , C07C237/36 , C07C237/42 , C07C243/38 , C07C271/56 , C07C271/58 , C07C275/24 , C07C275/26 , C07C275/28 , C07C275/30 , C07C275/34 , C07C275/36 , C07C275/38 , C07C275/42 , C07C275/60 , C07C275/62 , C07C311/47 , C07C317/22 , C07C317/32 , C07C317/42 , C07C323/21 , C07C323/44 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/42 , C07C2603/18 , C07C2603/68 , C07C2603/94 , C07D209/08 , C07D211/58 , C07D213/75 , C07D215/38 , C07D231/40 , C07D235/30 , C07D257/06 , C07D277/72 , C07D295/13 , C07D295/135 , C07D307/68 , C07D317/66 , C07D319/18 , C07D319/20 , C07D333/20 , C07D333/38 , C07D333/60 , C07D333/68 , C07D333/70 , C07D409/12 , C07D417/12 , C07D487/04
摘要: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
摘要翻译: 一类新颖的化合物,其作用是拮抗胰高血糖素激素对胰高血糖素受体的作用。 由于它们对胰高血糖素受体的拮抗作用,所述化合物可适用于治疗和/或预防任何胰高血糖素介导的病症和疾病如高血糖症,1型糖尿病,2型糖尿病和肥胖症。
-
公开(公告)号:US20070015757A1
公开(公告)日:2007-01-18
申请号:US11424871
申请日:2006-06-18
申请人: Peter Madsen , Jesper Lau , Janos Kodra , Inge Christensen
发明人: Peter Madsen , Jesper Lau , Janos Kodra , Inge Christensen
IPC分类号: A61K31/53 , A61K31/50 , A61K31/505 , A61K31/4965 , A61K31/455 , A61K31/433 , A61K31/426 , A61K31/425 , A61K31/421 , A61K31/42 , A61K31/4196 , A61K31/4192 , A61K31/415 , A61K31/381 , A61K31/35 , A61K31/34 , A61K31/198
CPC分类号: C07D207/323 , C07C235/84 , C07D233/96 , C07D237/08 , C07D261/18
摘要: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
摘要翻译: 用于拮抗胰高血糖素肽激素对胰高血糖素受体的作用的新型化合物。 更具体地,涉及胰高血糖素拮抗剂或反向激动剂。
-
公开(公告)号:US20050256175A1
公开(公告)日:2005-11-17
申请号:US11063117
申请日:2005-02-22
申请人: Jesper Lau , Inger Christensen , Peter Madsen , Paw Bloch , Carsten Behrens , Janos Kodra , Poul Nielsen
发明人: Jesper Lau , Inger Christensen , Peter Madsen , Paw Bloch , Carsten Behrens , Janos Kodra , Poul Nielsen
IPC分类号: A61K31/195 , A61K31/198 , A61K31/41 , A61K31/4439 , A61K45/06 , A61K31/428 , A61K31/426
CPC分类号: A61K45/06 , A61K31/195 , A61K31/198 , A61K31/41 , A61K31/4439 , A61K2300/00
摘要: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
摘要翻译: 用于拮抗胰高血糖素肽激素对胰高血糖素受体的作用的新型化合物。 更具体地,涉及胰高血糖素拮抗剂或反向激动剂。
-
公开(公告)号:US08883449B2
公开(公告)日:2014-11-11
申请号:US12251901
申请日:2008-10-15
摘要: The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues.
摘要翻译: 本发明涉及具有胰岛素活性的单链胰岛素,其包含通过6-11个氨基酸的连接肽连接的B和A链或经修饰的B和A链。 单链胰岛素将具有与人胰岛素相似或更低的生物胰岛素活性和IGF-1受体亲和力,并具有高的物理稳定性。 单链胰岛素可以在连接肽中含有至少一个碱性氨基酸残基。 单链胰岛素也可以在一个或多个Lys残基中酰化。
-
公开(公告)号:US20110213131A1
公开(公告)日:2011-09-01
申请号:US13063548
申请日:2009-09-11
申请人: Caspar Christensen , Rune Severinsen , Anders Klarskov Petersen , Steffen Kidal , Claus U. Jessen , Peter Madsen , Henrik Valore , Tina Møller Tagmose , Jan Lindy Sørensen
发明人: Caspar Christensen , Rune Severinsen , Anders Klarskov Petersen , Steffen Kidal , Claus U. Jessen , Peter Madsen , Henrik Valore , Tina Møller Tagmose , Jan Lindy Sørensen
CPC分类号: C07K1/1077 , A61K47/54 , C07K14/605 , C07K14/62
摘要: A method has for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described.
摘要翻译: 描述了选择性酰化具有两个或更多个反应性亲核官能团的肽或蛋白质中的氨基的方法。
-
公开(公告)号:US20110039769A1
公开(公告)日:2011-02-17
申请号:US12935438
申请日:2009-03-31
CPC分类号: A61K47/48284 , A61K47/643 , C07K14/62
摘要: Insulin albumin conjugates consisting of an insulin analogue, a bifunctional linker and albumin can efficiently be used to treat diabetic patients.
摘要翻译: 由胰岛素类似物,双功能接头和白蛋白组成的胰岛素白蛋白结合物可有效地用于治疗糖尿病患者。
-
公开(公告)号:US20090306337A1
公开(公告)日:2009-12-10
申请号:US12375678
申请日:2007-07-16
IPC分类号: C07K14/62
摘要: PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regulär insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.
摘要翻译: 聚乙二醇化的延长胰岛素是胰岛素,其与人胰岛素相比具有从A1,B1,A21和/或B30位置延伸的一个或多个延伸,所述延伸部分包含氨基酸残基(s) ),并且其中通过接头的PEG部分连接到延伸中的一个或多个氨基酸残基。 PEG是聚乙二醇。 这种聚乙二醇化的延长胰岛素具有比调节胰岛素更高的生物利用度和更长的时间作用特征,并且特别适合于肺部给药,并且可以方便地用于治疗糖尿病。
-
公开(公告)号:US20090170750A1
公开(公告)日:2009-07-02
申请号:US12251901
申请日:2008-10-15
申请人: Thomas Borglum Kjeldsen , Asser Sloth Andersen , Morten Schlein , Anders Robert Sorensen , Peter Madsen
发明人: Thomas Borglum Kjeldsen , Asser Sloth Andersen , Morten Schlein , Anders Robert Sorensen , Peter Madsen
摘要: The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues.
摘要翻译: 本发明涉及具有胰岛素活性的单链胰岛素,其包含通过6-11个氨基酸的连接肽连接的B和A链或经修饰的B和A链。 单链胰岛素将具有与人胰岛素相似或更低的生物胰岛素活性和IGF-1受体亲和力,并具有高的物理稳定性。 单链胰岛素可以在连接肽中含有至少一个碱性氨基酸残基。 单链胰岛素也可以在一个或多个Lys残基中酰化。
-
-
-
-
-
-
-
-
-